{"a":[{"_":"AZ, Ionis shares tumble on ATTR-CM trial flop, but analyst flags over-reaction","$":{"href":"/pharma/az-ionis-shares-tumble-attr-cm-trial-failure-it-over-reaction","hreflang":"en"}}]}
Phase 3negativeWainuaNegative
AI Analysis
Summary
AstraZeneca and Ionis' Wainua failed to meet its primary endpoint in the Phase 3 CARDIO-TTRansform trial for ATTR-CM, resulting in significant share price declines. The study did not demonstrate efficacy in reducing cardiovascular deaths or recurrent cardiovascular events through 140 weeks.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
CARDIO-TTRansform study did not meet primary endpoint of reducing cardiovascular deaths or recurrent cardiovascular events through 140 weeks
Importance:9/10
Sentiment:
-0.85
Phase 3 failureATTR-CMcardiovascularstock declineWainua
Read the original article
Published by FiercePharma on July 9, 2026 10:47 AM